SCOPUS 정보 검색 플랫폼

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 1, 2008, Pages 125-131

A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer

(4) O'Connor, T a Rustum, Y a Levine, E a Creaven, P a

a ROSWELL PARK CANCER INSTITUTE (United States)

Author keywords

Capecitabine; Chemotherapy; Irinotecan; Metastatic breast cancer; Phase I; S phase modulation

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLIN A; FLUOROURACIL; IRINOTECAN; TAXANE DERIVATIVE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE S PHASE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; TUMOR BIOPSY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BREAST NEOPLASMS; CAMPTOTHECIN; CYCLIN A; DEOXYCYTIDINE; DISEASE PROGRESSION; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; MAXIMUM TOLERATED DOSE; NEOPLASM METASTASIS; SURVIVAL ANALYSIS;

EID: 34848869099 PISSN: 03445704 EISSN: None Source Type: Journal
DOI: 10.1007/s00280-007-0456-1 Document Type: Article

Times cited : (10)

References (13)

1
- 33645526144
- Cancer statistics.
- 2
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics. CA Cancer J Clin 56(2):106-130
- (2006) CA Cancer J Clin , vol.56 , pp. 106-130
- Jemal, A.¹ Siegel, R.² Ward, E.³ Murray, T.⁴ Xu, J.⁵ Smigal, C.⁶ Thun, M.J.⁷

2
- 4344695312
- Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.
- 14
- Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22(14):2849-2855
- (2004) J Clin Oncol , vol.22 , pp. 2849-2855
- Perez, E.A.¹ Hillman, D.W.² Mailliard, J.A.³ Ingle, J.N.⁴ Ryan, J.M.⁵ Fitch, T.R.⁶ Rowland, K.M.⁷ Kardinal, C.G.⁸ Krook, J.E.⁹ Kugler, J.W.¹⁰ Dakhil, S.R.¹¹

3
- 0026638679
- Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin.
- 8
- Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Raschko JW, Somlo G, Blevins C (1992) Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin. J Clin Oncol 10(8):1278-1283
- (1992) J Clin Oncol , vol.10 , pp. 1278-1283
- Margolin, K.A.¹ Doroshow, J.H.² Akman, S.A.³ Leong, L.A.⁴ Morgan, R.J.⁵ Raschko, J.W.⁶ Somlo, G.⁷ Blevins, C.⁸

4
- 0024596992
- Refractory metastatic breast cancer: Salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium.
- 4
- Doroshow JH, Leong L, Margolin K, Flanagan B, Goldberg D, Bertrand M, Akman S, Carr B, Odujinrin O, Newman E, et al (1989) Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. J Clin Oncol 7(4):439-444
- (1989) J Clin Oncol , vol.7 , pp. 439-444
- Doroshow, J.H.¹ Leong, L.² Margolin, K.³ Flanagan, B.⁴ Goldberg, D.⁵ Bertrand, M.⁶ Akman, S.⁷ Carr, B.⁸ Odujinrin, O.⁹ Newman, E.¹⁰

5
- 0026036205
- 5-Fluorouracil plus leucovorin in women with metastatic breast cancer. a phase II study.
- 1
- Loprinzi CL, Ingle JN, Schaid DJ, Buckner JC, Edmonson JH, Allegra CJ (1991) 5-Fluorouracil plus leucovorin in women with metastatic breast cancer. A phase II study. Am J Clin Oncol 14(1):30-32
- (1991) Am J Clin Oncol , vol.14 , pp. 30-32
- Loprinzi, C.L.¹ Ingle, J.N.² Schaid, D.J.³ Buckner, J.C.⁴ Edmonson, J.H.⁵ Allegra, C.J.⁶

6
- 0024413739
- Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.
- 7
- Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ (1989) Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7(7):890-899
- (1989) J Clin Oncol , vol.7 , pp. 890-899
- Swain, S.M.¹ Lippman, M.E.² Egan, E.F.³ Drake, J.C.⁴ Steinberg, S.M.⁵ Allegra, C.J.⁶

7
- 0028180845
- Continuous 5-fluorouracil in the treatment of breast cancer.
- 1
- Cameron DA, Gabra H, Leonard RC (1994) Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 70(1):120-124
- (1994) Br J Cancer , vol.70 , pp. 120-124
- Cameron, D.A.¹ Gabra, H.² Leonard, R.C.³

8
- 0032127244
- Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.
- 8
- Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34(8):1274-1281
- (1998) Eur J Cancer , vol.34 , pp. 1274-1281
- Miwa, M.¹ Ura, M.² Nishida, M.³ Sawada, N.⁴ Ishikawa, T.⁵ Mori, K.⁶ Shimma, N.⁷ Umeda, I.⁸ Ishitsuka, H.⁹

9
- 0034016415
- Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
- 4
- Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45(4):291-297
- (2000) Cancer Chemother Pharmacol , vol.45 , pp. 291-297
- Schuller, J.¹ Cassidy, J.² Dumont, E.³ Roos, B.⁴ Durston, S.⁵ Banken, L.⁶ Utoh, M.⁷ Mori, K.⁸ Weidekamm, E.⁹ Reigner, B.¹⁰

10
- 0031771777
- Combination of irinotecan (CPT11) and 5- fluorouracil with an analysis of cellular determinants of drug activity.
- 10
- Pavillard V, Formento P, Rostagno P, Formento JL, Fischel JL, Francoual M, Etienne MC, Milano G (1998) Combination of irinotecan (CPT11) and 5- fluorouracil with an analysis of cellular determinants of drug activity. Biochem Pharmacol 56(10):1315-1322
- (1998) Biochem Pharmacol , vol.56 , pp. 1315-1322
- Pavillard, V.¹ Formento, P.² Rostagno, P.³ Formento, J.L.⁴ Fischel, J.L.⁵ Francoual, M.⁶ Etienne, M.C.⁷ Milano, G.⁸

11
- 0034660888
- Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: Role of drug sequence and dose.
- 14
- Cao S, Rustum YM (2000) Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res 60(14):3717-3721
- (2000) Cancer Res , vol.60 , pp. 3717-3721
- Cao, S.¹ Rustum, Y.M.²

12
- 27644598548
- S-phase modulation by irinotecan: Pilot studies in advanced solid tumors.
- 5
- Ramnath N, Khushalani N, Toth K, Litwin AM, Intengan ME, Slocum HK, Pendyala L, Smith PF, Stewart CC, Hoffman JL, Javle MM, Berdzik J, Creaven PJ, Rustum YM (2005) S-phase modulation by irinotecan: pilot studies in advanced solid tumors. Cancer Chemother Pharmacol 56(5):447-454
- (2005) Cancer Chemother Pharmacol , vol.56 , pp. 447-454
- Ramnath, N.¹ Khushalani, N.² Toth, K.³ Litwin, A.M.⁴ Intengan, M.E.⁵ Slocum, H.K.⁶ Pendyala, L.⁷ Smith, P.F.⁸ Stewart, C.C.⁹ Hoffman, J.L.¹⁰ Javle, M.M.¹¹ Berdzik, J.¹² Creaven, P.J.¹³ Rustum, Y.M.¹⁴

13
- 14644399903
- Synergistic antitumor activity of capecitabine in combination with irinotecan.
- 5
- Cao S, Durrani FA, Rustum YM (2005) Synergistic antitumor activity of capecitabine in combination with irinotecan. Clin Colorectal Cancer 4(5):336-343
- (2005) Clin Colorectal Cancer , vol.4 , pp. 336-343
- Cao, S.¹ Durrani, F.A.² Rustum, Y.M.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.